31472914
2019 Oct
In the past decade, there has been significant progress in the treatment of primary liver cancer. There has been increasing knowledge of the molecular alterations occurring in these tumors, which is now being translated into patient care. Ongoing clinical trials will further advance the therapeutic options available to patients, including the introduction of molecular targeted therapeutics and immunotherapy approaches. Critical to the success of these new drugs, is the appropriate use of them in the clinic to maximize efficacy and limit toxicity.
Cholangiocarcinoma; HCC; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Systemic treatment; Targeted therapy.
